# Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

> **NCT03414684** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 78 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03414684
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-01-30
- **Primary completion:** 2021-09-28
- **Final completion:** 2026-07-30
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03414684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03414684, "Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03414684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*